SecSonar.com

CytomX Therapeutics, Inc. (CTMX)

CytomX Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

CytomX Therapeutics, Inc. (CTMX) is a Biotechnology company based in US with a market capitalization of $582.2M. Revenue declined 44.8% year-over-year and free cash flow was negative at -$75.8M. This page tracks CTMX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 119 employees · IPO Oct 8, 2015

Valuation

Valuation & price

$3.61 · as of May 17, 2026 · -46.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

5.88

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$6.09$3.94$1.78Jul 25Dec 25Jul 26Jul 7, 25$2.37Jul 9, 25$2.49Jul 11, 25$2.42Jul 15, 25$2.40Jul 17, 25$2.38Jul 21, 25$2.38Jul 23, 25$2.43Jul 25, 25$2.40Jul 29, 25$2.25Jul 31, 25$2.19Aug 4, 25$2.39Aug 6, 25$2.17Aug 11, 25$2.31Aug 13, 25$1.78Aug 15, 25$1.91Aug 19, 25$2.00Aug 21, 25$2.03Aug 25, 25$2.00Aug 27, 25$2.07Aug 29, 25$2.04Sep 3, 25$2.12Sep 5, 25$2.28Sep 9, 25$2.09Sep 11, 25$2.09Sep 16, 25$1.96Sep 18, 25$2.04Sep 22, 25$2.06Sep 24, 25$2.41Sep 26, 25$2.90Sep 30, 25$3.19Oct 2, 25$3.28Oct 6, 25$3.28Oct 8, 25$3.37Oct 10, 25$3.36Oct 14, 25$3.42Oct 16, 25$3.28Oct 21, 25$3.62Oct 23, 25$3.30Oct 27, 25$3.36Oct 29, 25$3.26Oct 31, 25$3.57Nov 4, 25$4.09Nov 6, 25$4.19Nov 10, 25$4.19Nov 12, 25$4.23Nov 14, 25$3.88Nov 18, 25$3.66Nov 20, 25$3.77Nov 25, 25$4.15Nov 28, 25$4.28Dec 2, 25$3.81Dec 4, 25$4.08Dec 8, 25$3.87Dec 10, 25$3.90Dec 12, 25$4.19Dec 16, 25$4.25Dec 18, 25$3.88Dec 22, 25$4.12Dec 24, 25$4.40Dec 29, 25$4.19Jan 2, 26$4.25Jan 6, 26$4.14Jan 8, 26$4.26Jan 12, 26$4.34Jan 14, 26$4.30Jan 16, 26$5.39Jan 21, 26$5.29Jan 23, 26$5.54Jan 27, 26$5.93Jan 29, 26$5.74Feb 2, 26$6.09Feb 4, 26$5.67Feb 9, 26$5.70Feb 11, 26$5.56Feb 13, 26$5.32Feb 18, 26$5.41Feb 20, 26$5.43Feb 24, 26$5.44Feb 26, 26$5.48Mar 2, 26$5.34Mar 4, 26$5.07Mar 6, 26$4.68Mar 10, 26$4.88Mar 12, 26$4.87Mar 17, 26$5.45Mar 19, 26$4.78Mar 23, 26$4.46Mar 25, 26$4.22Mar 27, 26$4.52Mar 31, 26$4.70Apr 2, 26$4.56Apr 7, 26$4.30Apr 9, 26$4.24Apr 13, 26$4.39Apr 15, 26$4.56Apr 17, 26$4.82Apr 22, 26$4.61Apr 24, 26$4.40Apr 28, 26$4.12Apr 30, 26$4.22May 4, 26$4.18May 6, 26$4.13May 8, 26$3.98May 12, 26$3.88May 14, 26$3.78May 18, 26$3.50May 20, 26$3.72May 22, 26$3.76May 28, 26$3.71Jun 1, 26$3.45Jun 3, 26$3.22Jun 5, 26$3.00Jun 9, 26$2.98Jun 11, 26$2.98Jun 15, 26$3.04Jun 17, 26$2.96Jun 22, 26$3.04Jun 24, 26$3.32Jun 26, 26$3.40Jul 2, 26$3.73
$1.7652-week range$6.75
Loading valuation history…

Fundamentals

Key fundamentals

$582.2M

Market cap

-44.8%

Revenue growth (YoY)

100.0%

Gross margin

-$75.8M

Free cash flow (USD)

-$132.8M

Net debt

Net cash position

63.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$15.0MFY 2017$71.6MFY 2018$59.5MFY 2019$57.5MFY 2020$68.4MFY 2021$37.3MFY 2022$53.2MFY 2023$101.2MFY 2024$138.1MFY 2025$76.2M
$15M$76.2M

Free cash flow by year

2016 → 2025

FY 2016$-4.2MFY 2017$168.8MFY 2018$-79.3MFY 2019$-144.0MFY 2020$3.0MFY 2021$-120.6MFY 2022$-112.5MFY 2023$-56.9MFY 2024$-86.5MFY 2025$-75.8M
-$4.2M-$75.8M

Gross margin by year

2021 → 2025

FY 2021100.0%FY 2022100.0%FY 2023100.0%FY 2024100.0%FY 2025100.0%
100.0%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

1

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 7, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventEquity Incentive Plan AmendedJun 22, 2026Filing
  • Insider sellInsider Sell $5KOgden Christopher · Chief Financial Officer · $5KJun 17, 2026Filing
  • 8-K eventCollaboration Agreement AmendmentJun 3, 2026Filing
  • Quarterly report10-Q FiledMay 7, 2026Filing
  • 8-K eventQ1 2026 Financial ResultsMay 7, 2026Filing

Questions

Frequently asked questions

What is CytomX Therapeutics, Inc.'s market cap?

CytomX Therapeutics, Inc. (CTMX) has a market capitalization of $582.2M.

What is CTMX's P/E ratio?

A meaningful P/E ratio is not available for CTMX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is CTMX's price-to-book (P/B) ratio?

CTMX trades at 5.88 times book value per share.

Are insiders buying CTMX stock?

SEC Form 4 filings show no open-market insider buys at CytomX Therapeutics, Inc. in the last 90 days (1 sell).

Same arena

Related companies in Biotechnology

GYRE

Gyre Therapeutics, Inc.

$572.7M

ARVN

Arvinas, Inc.

$572M

CBIO

Crescent Biopharma, Inc.

$598.3M

VALN

Valneva SE

$563.3M

RIGL

Rigel Pharmaceuticals, Inc.

$562.1M

MDXG

MiMedx Group, Inc.

$553.3M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.